|Bid||4.2500 x 0|
|Ask||4.4700 x 0|
|Day's Range||4.2000 - 4.2100|
|52 Week Range||0.0470 - 7.2000|
|Beta (5Y Monthly)||0.54|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
The acquired patches, marketed under the brands CardioCel® and VascuCel®, are processed in a manner that is intended to reduce the risk of calcification. Annualized 2019 sales of these product lines were $7.1 million, mostly in the US and Europe. Guidance on how this acquisition may affect LeMaitre Vascular’s 2019 revenue, operating income and EPS expectations will be provided at the Company’s Q3 2019 earnings call on October 23, 2019.